微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 75.25% | 4.42% | -0.08% | 27/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 75.31% | 5.89% | -0.01% | 25/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 75.32% | 5.42% | 3.69% | 23/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 72.64% | 5.93% | 0.8% | 29/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 72.07% | 5.88% | 1.32% | 29/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 71.13% | 3.18% | -0.46% | 33/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 71.45% | 0.72% | 4.2% | 28/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 68.58% | -4.04% | 0.75% | 35/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 68.06% | -8.23% | -1.26% | 37/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 68.93% | -8.03% | -2.83% | 37/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 70.94% | -5.49% | -0.73% | 34/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 71.46% | -3.51% | -3.64% | 36/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 74.17% | -0.3% | -1.05% | 34/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 74.95% | 2.59% | -0.15% | 34/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 75.07% | 4.35% | 1.36% | 32/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 74.06% | 7.27% | -0.44% | 35/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 74.39% | 7.29% | 1.82% | 29/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 73.06% | 8% | 1.56% | 31/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 71.94% | -3.08% | 4.19% | 29/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 69.05% | -11.96% | -0.41% | 41/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 69.33% | -12.28% | 2.49% | 35/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 67.65% | -14.87% | -8.87% | 36/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 74.23% | -6.65% | -5.36% | 24/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 78.43% | -1.61% | -0.78% | 21/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 79.04% | -2.07% | -0.53% | 13/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 79.47% | -1.01% | -0.06% | 17/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 79.52% | -2.13% | -0.25% | 15/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 79.71% | -1.71% | -1.24% | 21/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 80.72% | 0.26% | 0.55% | 13/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 80.27% | 1.09% | -1.19% | 13/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 81.25% | 2.28% | 0.18% | 12/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 81.1% | 7.82% | 0.73% | 14/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 80.51% | 8.29% | 1.39% | 7/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 79.41% | 6.58% | -0.03% | 8/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 79.43% | 4% | 5.6% | 6/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 75.22% | 1.97% | 1.18% | 14/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 74.35% | 0.64% | -0.21% | 10/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 74.5% | 0.26% | -2.45% | 9/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 76.38% | -1.44% | 3.54% | 7/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 73.77% | 0.41% | -0.15% | 10/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 73.88% | -3.67% | -0.58% | 9/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 74.31% | -3.01% | -4.11% | 8/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 77.49% | -0.15% | 5.48% | 5/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |